Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK
Nathalie Conrad(University of Oxford), Jan Y. Verbakel(University of Oxford), John J.V. McMurray(Western Infirmary), Laura Goetschalckx(KU Leuven), Geert Molenberghs(Transnational University Limburg), Thomas Callender(George Institute for Global Health), Geraldine Cambridge(University College London), Geert Verbeke(Hasselt University), Justin C Mason(Imperial College London), Kazem Rahimi(University of Oxford)
Cited by 408
Related Papers
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Dapagliflozin in Patients with Chronic Kidney Disease
|New England Journal of Medicine|2020|5.2k
Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis
|The Lancet|2015|3.7k
ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012
|European Journal of Heart Failure|2012|2.6k